Overhaul could cut UK brand prices 20%
This article was originally published in Scrip
Prices of branded medicines used in the UK could undergo cuts of between 10% and 20%, according to a government consultation on proposals for changing the pricing of drugs used on the National Health Service.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.